Last reviewed · How we verify
Enoblituzumab Schedule 2
At a glance
| Generic name | Enoblituzumab Schedule 2 |
|---|---|
| Also known as | MGA271 |
| Sponsor | MacroGenics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enoblituzumab Schedule 2 CI brief — competitive landscape report
- Enoblituzumab Schedule 2 updates RSS · CI watch RSS
- MacroGenics portfolio CI